Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 8359.00
PTN's Cash to Debt is ranked higher than
76% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. PTN: 8359.00 )
PTN' s 10-Year Cash to Debt Range
Min: 1.4   Max: No Debt
Current: 8359

F-Score: 3
Z-Score: -17.98
M-Score: -4.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -155850.00
PTN's Operating margin (%) is ranked lower than
58% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. PTN: -155850.00 )
PTN' s 10-Year Operating margin (%) Range
Min: -155850   Max: -21.25
Current: -155850

-155850
-21.25
Net-margin (%) -208620.00
PTN's Net-margin (%) is ranked lower than
59% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. PTN: -208620.00 )
PTN' s 10-Year Net-margin (%) Range
Min: -208620   Max: -12.64
Current: -208620

-208620
-12.64
ROE (%) -90.79
PTN's ROE (%) is ranked lower than
52% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. PTN: -90.79 )
PTN' s 10-Year ROE (%) Range
Min: -4000   Max: -19.24
Current: -90.79

-4000
-19.24
ROA (%) -83.20
PTN's ROA (%) is ranked lower than
52% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. PTN: -83.20 )
PTN' s 10-Year ROA (%) Range
Min: -320.69   Max: -14.47
Current: -83.2

-320.69
-14.47
ROC (Joel Greenblatt) (%) -5859.02
PTN's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. PTN: -5859.02 )
PTN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5888.71   Max: -126.21
Current: -5859.02

-5888.71
-126.21
Revenue Growth (%) -100.00
PTN's Revenue Growth (%) is ranked lower than
52% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. PTN: -100.00 )
PTN' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 155.4
Current: -100

-100
155.4
EBITDA Growth (%) 15.30
PTN's EBITDA Growth (%) is ranked higher than
89% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. PTN: 15.30 )
PTN' s 10-Year EBITDA Growth (%) Range
Min: -65.2   Max: 15.3
Current: 15.3

-65.2
15.3
EPS Growth (%) 5.30
PTN's EPS Growth (%) is ranked higher than
76% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. PTN: 5.30 )
PTN' s 10-Year EPS Growth (%) Range
Min: -63.3   Max: 5.3
Current: 5.3

-63.3
5.3
» PTN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PTN Guru Trades in Q3 2013

Chuck Royce 35,000 sh (unchged)
» More
Q4 2013

PTN Guru Trades in Q4 2013

Chuck Royce 35,000 sh (unchged)
» More
Q1 2014

PTN Guru Trades in Q1 2014

Chuck Royce 35,000 sh (unchged)
» More
Q2 2014

PTN Guru Trades in Q2 2014

Chuck Royce 35,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PTN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-06-30 Sold Out $0.578 - $0.67 $ 0.8539%0
Jean-Marie Eveillard 2013-03-31 Reduce -84.35%$0.551 - $0.68 $ 0.8537%121094
Jean-Marie Eveillard 2012-09-30 Reduce -53.47%$0.48 - $0.75 $ 0.8529%773660
Jean-Marie Eveillard 2011-12-31 Add 72.72%$0.4019 - $0.6789 $ 0.8554%1662543
Jean-Marie Eveillard 2011-09-30 Add 35.1%$0.5032 - $1.14 $ 0.851%962543
Jean-Marie Eveillard 2011-06-30 Reduce -54.36%0.01%$0.82 - $1.08 $ 0.85-6%712443
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.36
PTN's P/B is ranked higher than
76% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. PTN: 2.36 )
PTN' s 10-Year P/B Range
Min: 1.18   Max: 205
Current: 2.36

1.18
205
EV-to-EBIT -1.01
PTN's EV-to-EBIT is ranked higher than
66% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 168.09 vs. PTN: -1.01 )
PTN' s 10-Year EV-to-EBIT Range
Min: 5.1   Max: 21.6
Current: -1.01

5.1
21.6
Current Ratio 5.07
PTN's Current Ratio is ranked higher than
86% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.89 vs. PTN: 5.07 )
PTN' s 10-Year Current Ratio Range
Min: 1   Max: 21.07
Current: 5.07

1
21.07
Quick Ratio 5.07
PTN's Quick Ratio is ranked higher than
87% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.47 vs. PTN: 5.07 )
PTN' s 10-Year Quick Ratio Range
Min: 1   Max: 21.07
Current: 5.07

1
21.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.50
PTN's Price/Net Cash is ranked higher than
98% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PTN: 2.50 )
PTN' s 10-Year Price/Net Cash Range
Min: 0.76   Max: 271.11
Current: 2.5

0.76
271.11
Price/Net Current Asset Value 2.50
PTN's Price/Net Current Asset Value is ranked higher than
97% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PTN: 2.50 )
PTN' s 10-Year Price/Net Current Asset Value Range
Min: 0.76   Max: 128.42
Current: 2.5

0.76
128.42
Price/Tangible Book 2.36
PTN's Price/Tangible Book is ranked higher than
87% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.85 vs. PTN: 2.36 )
PTN' s 10-Year Price/Tangible Book Range
Min: 0.74   Max: 193.57
Current: 2.36

0.74
193.57
Earnings Yield (Greenblatt) 1477.20
PTN's Earnings Yield (Greenblatt) is ranked higher than
95% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. PTN: 1477.20 )
PTN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.6   Max: 19.6
Current: 1477.2

4.6
19.6
Forward Rate of Return (Yacktman) -48.63
PTN's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. PTN: -48.63 )
PTN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -100.7   Max: -65.4
Current: -48.63

-100.7
-65.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:PTNA.Germany
Palatin Technologies, Inc. was incorporated in Delaware in 1986 and commenced operations in the biopharmaceutical area in 1996. It is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems. It has a pipeline of development programs targeting melanocortin and natriuretic receptors, including development of proposed products for treatment of sexual dysfunction, acute asthma, heart failure, hypertension, obesity, diabetes and metabolic syndrome. The Company currently has the following active drug development programs: Bremelanotide, a peptide melanocortin receptor agonist, for treatment of sexual dysfunction, targeting female sexual dysfunction (FSD) and erectile dysfunction (ED) in patients non-responsive to current therapies; Peptide melanocortin receptor agonists for treatment of FSD, ED, and other indications; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, for treatment of acute exacerbations of asthma, heart failure and refractory or difficult-to-control hypertension. The FDA, comparable agencies in other countries and state regulatory authorities have established regulations and guidelines which apply to, among other things, the clinical testing, manufacturing, safety, efficacy, labeling, storage, record keeping, advertising, promotion, marketing and distribution of its proposed products.
» More Articles for PTN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific... Jul 09 2014
Palatin Technologies to Join Russell Microcap Index Jun 27 2014
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 20 2014
Palatin Technologies Announces Notification of Patent Allowance On Next Generation Melanocortin... Jun 10 2014
PALATIN TECHNOLOGIES INC Financials May 20 2014
Palatin Technologies, Inc (PTN) CEO Carl Spana on Q3 2014 Results - Earnings Call Transcript May 13 2014
Palatin Technologies Earnings Call scheduled for 11:00 am ET today May 13 2014
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition May 13 2014
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2014 Results; Teleconference and... May 13 2014
PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report May 12 2014
Palatin Technologies, Inc. To Report Third Quarter Fiscal Year 2014 Results May 09 2014
Palatin Technologies Presents at the American Psychiatric Association (APA) May 06 2014
Palatin Technologies Announces Option Exercise by Specialty Pharmaceutical Company to License... May 01 2014
Palatin Technologies Presents at the Annual Clinical Meeting of the American College of... Apr 29 2014
Palatin Technologies Inc. (PTN) Jumps: Stock Up 8.1% Apr 02 2014
Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe Mar 31 2014
Palatin Technologies (PTN) Worth Watching: Stock Soars 15.6% Mar 20 2014
Palatin Technologies to present at the 26th Annual ROTH Conference Mar 06 2014
Palatin Technologies To Present At The 26Th Annual ROTH Conference Mar 06 2014
Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in... Feb 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK